XT1061, an optimized HBV capsid assembly modulator, advances through Phase I
- Structural optimization of the earlier capsid assembly modulator GLP-26 gave compound 39, named XT1061, with very strong anti-HBV activity in cells.
- In an AAV/HBV mouse model it rapidly lowered HBV DNA and held it down during dosing; combining it with pradefovir mesylate clearly beat either drug alone.
- Preclinical work and a Phase I trial pointed to good drug-like properties and low safety concern, supporting development toward functional cure.
💡 Points Based on the abstract
Building on GLP-26 makes this an incremental, lower-risk step over earlier capsid assembly modulators, so the real question is differentiation. Readouts beyond DNA suppression, such as cccDNA and surface antigen, matter here. And because the mouse model captures cccDNA biology poorly, the pradefovir benefit needs testing for true synergy.